GPER, for example, is overexpressed in seminomas, melanomas, some ovarian cancers, lung cancers (NSCLC), insulin-resistant endometrial cancer models, and the vast majority of breast cancer models (particularly triple negative breast cancer, TNBC). Here, GPER1 is linked to triple-negative breast carcinoma.